NeoGenomics, Inc. Interest Expense Nonoperating
NeoGenomics, Inc. (NEO) reported Interest Expense Nonoperating of $781.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Expense Statement
us-gaap:InterestExpenseNonoperating · last filed 2026-07-28
- NeoGenomics, Inc. interest expense nonoperating for the quarter ending 2026-06-30 was $781.00K, a 16.29% decline year-over-year.
- NeoGenomics, Inc. interest expense nonoperating for the quarter ending 2026-03-31 was $598.00K, a 63.04% decline year-over-year.
- NeoGenomics, Inc. interest expense nonoperating for the quarter ending 2025-12-31 was $599.00K, a 63.12% decline year-over-year.
- NeoGenomics, Inc. interest expense nonoperating for the quarter ending 2025-09-30 was $603.00K, a 63.28% decline year-over-year.
- NeoGenomics, Inc. interest expense nonoperating for fiscal 2025 was $3.75M, a 43.28% decline from fiscal 2024.
- NeoGenomics, Inc. interest expense nonoperating for fiscal 2024 was $6.62M, a 4.20% decline from fiscal 2023.
- NeoGenomics, Inc. interest expense nonoperating for fiscal 2023 was $6.91M, a 8.89% decline from fiscal 2022.
- NeoGenomics, Inc. interest expense nonoperating for fiscal 2022 was $7.58M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $781.00K 10-Q · filed 2026-07-28 | $1.38M 10-Q · filed 2026-07-28 | $1.98M derived: sum of 3 quarters · filed 2026-07-28 | $2.58M derived: sum of 4 quarters · filed 2026-07-28 |
| 2026-03-31 | $598.00K 10-Q · filed 2026-04-28 | $1.20M derived: sum of 2 quarters · filed 2026-04-28 | $1.80M derived: sum of 3 quarters · filed 2026-04-28 | $2.73M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-12-31 | $599.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $1.20M derived: sum of 2 quarters · filed 2026-02-17 | $2.13M derived: sum of 3 quarters · filed 2026-07-28 | $3.75M 10-K · filed 2026-02-17 |
| 2025-09-30 | $603.00K 10-Q · filed 2025-10-28 | $1.54M derived: sum of 2 quarters · filed 2026-07-28 | $3.15M 10-Q · filed 2025-10-28 | $4.78M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-06-30 | $933.00K 10-Q · filed 2026-07-28 | $2.55M 10-Q · filed 2026-07-28 | $4.17M derived: sum of 3 quarters · filed 2026-07-28 | $5.82M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-03-31 | $1.62M 10-Q · filed 2026-04-28 | $3.24M derived: sum of 2 quarters · filed 2026-04-28 | $4.88M derived: sum of 3 quarters · filed 2026-04-28 | $6.55M derived: sum of 4 quarters · filed 2026-04-28 |
| 2024-12-31 | $1.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $3.27M derived: sum of 2 quarters · filed 2026-02-17 | $4.93M derived: sum of 3 quarters · filed 2026-02-17 | $6.62M 10-K · filed 2026-02-17 |
| 2024-09-30 | $1.64M 10-Q · filed 2025-10-28 | $3.31M derived: sum of 2 quarters · filed 2025-10-28 | $4.99M 10-Q · filed 2025-10-28 | $6.67M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $1.67M 10-Q · filed 2025-07-29 | $3.35M 10-Q · filed 2025-07-29 | $5.03M derived: sum of 3 quarters · filed 2026-02-17 | $6.72M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | $1.69M 10-Q · filed 2025-04-29 | $3.37M derived: sum of 2 quarters · filed 2026-02-17 | $5.05M derived: sum of 3 quarters · filed 2026-02-17 | $6.83M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $1.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $3.37M derived: sum of 2 quarters · filed 2026-02-17 | $5.15M derived: sum of 3 quarters · filed 2026-02-17 | $6.91M 10-K · filed 2026-02-17 |
| 2023-09-30 | $1.69M 10-Q · filed 2024-11-05 | $3.47M derived: sum of 2 quarters · filed 2024-11-05 | $5.23M 10-Q · filed 2024-11-05 | |
| 2023-06-30 | $1.78M 10-Q · filed 2024-07-30 | $3.54M 10-Q · filed 2024-07-30 | ||
| 2022-12-31 | $7.58M 10-K · filed 2025-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |